UK – NICE draft ‘no’ for Roche’s Tecentriq

The National Institute for Health and Care Excellence says it is looking to Roche to ensure a new treatment for advanced breast cancer with significant unmet need is cost-effective.

The cost watchdog published draft guidelines rejecting the PD-L1 inhibitor Tecentriq (atezolizumab) for breast cancer that has spread to other parts of the body, ruling that based on current evidence it is too expensive for NHS use.

Tecentriq given with the chemotherapy agent nab-paclitaxel is the first immunotherapy that specifically targets triple negative breast cancer where tumours have PD-L1 expression of 1% or more. It is given to people who have not had prior chemotherapy for metastatic disease and where surgery to remove the tumour is not possible.

Evidence indicates that the combination extends progression free survival by around 2.5 months compared to placebo plus nab-paclitaxel (7.5 months versus 5.0 months respectively), and increases overall survival by around 9.5 months (25.0 months versus 15.5 months respectively)…